Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
Chronic Myelomonocytic Leukemia (CMML)
- Supportive Therapy for the Person with Chronic Myelomonocytic Leukemia (CMML)
- Chemotherapy for Chronic Myelomonocytic Leukemia (CMML)
- Growth Factors and Similar Medicines for Chronic Myelomonocytic Leukemia
- Radiation Therapy for Chronic Myelomonocytic Leukemia (CMML)
- Surgery for Chronic Myelomonocytic Leukemia (CMML)
- Stem Cell Transplant for Chronic Myelomonocytic Leukemia (CMML)
- General Approach to Treating Chronic Myelomonocytic Leukemia (CMML)
- References: Chronic Myelomonocytic Leukemia
- If You Have Chronic Myelomonocytic Leukemia (CMML)
General Approach to Treating Chronic Myelomonocytic Leukemia (CMML)
Treatment for people with chronic myelomonocytic leukemia (CMML) depends on a number of factors, such as:
- A person's age and overall health (including if a person is eligible for a stem cell transplant)
- If the CMML is causing symptoms, and how fast it seems to be progressing
- If the CMML is in a higher- or lower-risk group
- A person's preferences and goals for treatment
In general, a stem cell transplant (SCT) is the only realistic way to try to cure CMML, while other treatments are aimed at treating symptoms CMML causes and possibly slowing its progression.
An SCT may be the treatment of choice for younger people with higher-risk CMML, if a matched stem cell donor is available. Advances in SCT means this treatment might also be an option for some older patients as well. In general, SCT hasn't been shown to be better than other treatments in people with lower-risk CMML.
If SCT is not an option, the goal is to relieve symptoms while limiting complications and reducing side effects. Supportive care, such as transfusions, blood cell growth factors, and antibiotics to treat infections, is used to treat all people with CMML so they can live as long as possible.
In people who aren't having symptoms from CMML, treatment might not be needed right away. The doctors may instead just watch the CMML closely. If treatment is needed, chemotherapy is typically the first choice, with either hydroxyurea or one of the hypomethylating agents (azacitidine or decitabine). The choice often depends on what types of symptoms a person is having that need to be controlled. For example:
- A major benefit receiving azacitidine or decitabine is less need for blood transfusions and an improved quality of life. If the CMML responds, people are often less fatigued and are able to function more normally.
- Treatment with hydroxyurea can help some people with high white blood cell counts. This drug can help lower monocyte counts and decrease the need for transfusions. It can also shrink the spleen to help the person feel more comfortable.
If one type of drug doesn't work, often another can be tried.
Because CMML can often be hard to treat, taking part in a clinical trial testing a newer treatment might be a good option for some people.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
National Cancer Institute. Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version. 2022. Accessed at https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq on May 20, 2024.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Myelodysplastic Syndromes. Version 1.2024. Accessed at https://www.nccn.org on May 18, 2024.
Padron E. Chronic myelomonocytic leukemia: Management and prognosis. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/chronic-myelomonocytic-leukemia-management-and-prognosis on May 18, 2024.
Sekeres MA, Platzbecker U. Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS. UpToDate. 2024. Accessed at https://www.uptodate.com/contents/myelodysplastic-syndromes-neoplasms-mds-management-of-hematologic-complications-in-lower-risk-mds on May 18, 2024.
Last Revised: May 21, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.